Cyclosporine A for neuroprotection: establishing dosing guidelines for safe and effective use. - Wikidata - awgldk - TriplyDB

Cyclosporine A for neuroprotection: establishing dosing guidelines for safe and effective use.

Cyclosporine A for neuroprotection: establishing dosing guidelines for safe and effective use.

http://www.wikidata.org/entity/Q37528454

about

Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury Traumatic brain injury: an overview of pathobiology with emphasis on military populations.Cyclophilin D-sensitive mitochondrial permeability transition in adult human brain and liver mitochondria.Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor ® EL Post-injury administration of the mitochondrial permeability transition pore inhibitor, NIM811, is neuroprotective and improves cognition after traumatic brain injury in rats Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?Cellular alterations in human traumatic brain injury: changes in mitochondrial morphology reflect regional levels of injury severity.Mitochondrial polymorphisms impact outcomes after severe traumatic brain injury Neuroprotection Trials in Traumatic Brain Injury.Opa1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendropathy.Methods of Drug Delivery in Neurotrauma.The clinical value of enzyme-multiplied immunoassay technique monitoring the plasma concentrations of cyclosporine A after renal transplantation.

P2860

Q24626804-A0A665BE-C391-4AA4-8680-B6D4785E5509 Q33791943-CAA78AED-17FA-4124-B424-170519BCD54B Q34152722-D611C373-9844-4ED8-85DB-128F41B4B657 Q34313613-A73DF812-B66C-408D-A17F-EEE635737C63 Q35212561-7F733F15-6FFC-43E9-9710-16E1CDB58294 Q35589949-50B92679-6562-4E62-85DB-67AB4E7C8EBB Q36661189-376E82D7-ACF9-40BB-B66B-146155E36068 Q37430656-76CDF007-09DF-49D1-A854-6C02EFC9E09B Q38736275-2A4154B0-CF2F-45F7-886C-84744A9493C5 Q42917454-EFA7F993-6586-4FB0-A671-40912E59EAB7 Q48525432-BDF125D4-2CCF-4E22-A45D-356DB3A9F0FF Q50043110-0DD22555-1688-44C5-988C-B747769ED12D

P2860

Cyclosporine A for neuroprotection: establishing dosing guidelines for safe and effective use.

http://www.wikidata.org/entity/Q37528454

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cyclosporine A for neuroprotec ...... es for safe and effective use.

@en

Cyclosporine A for neuroprotec ...... es for safe and effective use.

@nl

type

label

Cyclosporine A for neuroprotec ...... es for safe and effective use.

@en

Cyclosporine A for neuroprotec ...... es for safe and effective use.

@nl

prefLabel

Cyclosporine A for neuroprotec ...... es for safe and effective use.

@en

Cyclosporine A for neuroprotec ...... es for safe and effective use.

@nl

P1433

Q37528454-01893B13-30B4-4CC5-990F-3E2F2B4A2C40

P1476

Q37528454-6344AE5E-32A8-45D9-B3A4-9AA70545218B

P2093

Q37528454-33656BD4-EB98-47DF-879E-F20FCEF953E1

Q37528454-86A89436-6333-48D8-83B8-9C2EB0B9F2D6

Q37528454-90291C2B-964C-4B0D-8B32-11F501309EF1

Q37528454-C2FD0B32-BC5B-4576-80C2-4FFB813B96D7

P2860

Q37528454-00526895-299D-4E93-AE54-655EF7C2BB3B

Q37528454-0D1F24EF-D248-464E-BEE9-300659800AEF

Q37528454-16E8C458-3346-4942-A03B-B341F697053E

Q37528454-1EC14762-EE6B-422E-B0C7-227D28B96269

Q37528454-20D2BA3B-EA50-4398-BD22-DEBF7311DAD8

Q37528454-2BD8EA45-4D8A-43C8-AB56-57EBDBD8E4D4

Q37528454-2EEFA6A5-72FC-46F4-8779-E57D157AD8F9

Q37528454-393BC39F-583D-4F45-BB8A-5B89EEC9D005

Q37528454-597ED391-78B3-4666-8740-5FF4875E66DC

Q37528454-5CF40568-FFE6-436F-B563-7B1372D45636

P304

Q37528454-AD5397EA-9634-4634-AD96-7790613BBB0D

P31

Q37528454-67D18C33-C7C0-40A1-93B5-088A2795301A

P356

Q37528454-6FD4E68F-6079-4D52-B9B2-CDD2E42341B4

P407

Q37528454-3A39118D-D368-440B-84BD-18BDD1C272B3

P433

Q37528454-71AFB0AF-BFC6-48C6-854E-10B9C9DE66B8

P478

Q37528454-C31BE259-DDBB-4F4E-BF1E-A38A0926CCF5

P577

Q37528454-24E59855-BC91-4370-88F6-A97740A60926

P698

Q37528454-AEF4CC91-2308-445A-8B58-F9F28A5F5724

P356

14740330903066742

P1433

Expert Opinion on Drug Safety

P1476

Cyclosporine A for neuroprotec ...... es for safe and effective use.

@en

P2093

Aaron M Cook

http://www.w3.org/2001/XMLSchema#string

Byron Young

http://www.w3.org/2001/XMLSchema#string

Jimmi Hatton

http://www.w3.org/2001/XMLSchema#string

Justin Whitlow

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives.

Cyclosporin pharmacokinetics in the elderly.

Dose-response curve and optimal dosing regimen of cyclosporin A after traumatic brain injury in rats.

Drug resistance in brain diseases and the role of drug efflux transporters.

A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures.

Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications.

Pharmacological treatment of traumatic brain injury: a review of agents in development.

Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial.

Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.

Management of head trauma.

P304

411-419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740330903066742

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19548859

http://www.w3.org/2001/XMLSchema#string